Chamath Palihapitiya Joins Forces with Eli Lilly to Target LDL Cholesterol with Gene‑Editing Therapy

When you hear the name Chamath Palihapitiya, you probably picture bold bets on Bitcoin, SPACs, or that sudden pivot into space‑flight finance. This time, however, he’s zeroing in on something a little less flashy but arguably more consequential for everyday health: a gene‑therapy that could cut the “bad” cholesterol that clogs arteries.

In a press release that landed on Bloomberg and other wire services last week, Palihapitiya’s venture firm Social Capital announced a multi‑year partnership with Eli Lilly. The goal? To build a CRISPR‑based therapy that permanently knocks out PCSK9 – a liver‑produced protein that, when overactive, keeps low‑density lipoprotein (LDL) levels stubbornly high.

Why PCSK9? It’s not new science. Researchers have known for a decade that inhibiting this protein can drop LDL by up to 60 percent, and several monoclonal‑antibody drugs already sit on the market. What’s novel here is the idea of a single‑dose, one‑time gene edit that does the job for life, sparing patients the recurring injections and the high cost that comes with them.

The biotech angle is what really caught my eye. Eli Lilly, traditionally a heavyweight in small‑molecule drugs, has been nudging into the gene‑editing arena for a few years now – think of its work on RNA‑based medicines and recent collaborations with CRISPR innovators. By teaming up with a high‑profile investor like Palihapitiya, Lilly is essentially putting a megaphone on its own ambitions.

From a financial standpoint, the deal makes a lot of sense. Palihapitiya’s Social Capital has been stacking a portfolio of early‑stage biotech firms, many of which are chasing the same “cure‑once‑and‑for‑all” narrative. By pooling resources with Lilly’s massive R&D budget and regulatory expertise, the partnership can accelerate pre‑clinical work, move faster into human trials, and hopefully avoid the typical pitfalls that send promising gene‑therapy candidates into the trash.

There are, of course, risks. Gene editing in humans is still a delicate dance, and off‑target effects remain a lingering worry. Regulators will likely scrutinize any approach that edits the genome, even if it’s somatic (non‑inheritable). Moreover, the market is already gearing up for competition from other PCSK9‑targeting platforms, both antibody‑based and RNA‑interference.

Still, the excitement is palpable. If the Palihapitiya‑Lilly team can demonstrate a safe, durable reduction in LDL with a single treatment, the implications could ripple far beyond cardiovascular disease – we could be looking at a template for tackling a host of chronic conditions via permanent genetic tweaks.

For investors, the signal is clear: the intersection of deep‑pocket pharma and venture‑backed biotech innovation is where the next wave of high‑impact, high‑return therapies might be born. And for patients, a future where a quick outpatient procedure replaces a lifetime of pills and injections is, frankly, a game‑changer.